Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7837668 | 1.00 | KDM4E (0.71) | KDM4ESMN1; SMN2POLBTSHRNPSR1 | |
| SCHEMBL5950255 | 0.85 | KDM4E (0.73) | KDM4ESMN1; SMN2POLBTSHRNPSR1 | |
| SCHEMBL6534174 | 0.85 | KDM4E (0.73) | KDM4ESMN1; SMN2POLBTSHRNPSR1 | |
| SCHEMBL7837671 | 0.82 | KDM4E (0.69) | KDM4ESMN1; SMN2POLBTSHRNPSR1 | |
| SCHEMBL7670891 | 0.82 | KDM4E (0.69) | KDM4ESMN1; SMN2POLBTSHRNPSR1 | |
| SCHEMBL9977731 | 0.76 | KDM4E (0.61) | KDM4ESMN1; SMN2POLBTSHRNPSR1 | |
| SCHEMBL18051877 | 0.76 | KDM4E (0.61) | KDM4ESMN1; SMN2POLBTSHRNPSR1 | |
| SCHEMBL5736424 | 0.76 | KDM4E (0.66) | KDM4ESMN1; SMN2POLBTSHRNPSR1 | |
| SCHEMBL7677217 | 0.75 | KDM4E (0.41) | KDM4ESMN1; SMN2KMT2A | |
| SCHEMBL7680329 | 0.75 | LMNA (0.44) | KDM4ESMN1; SMN2POLBNPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020049199-A1 | N-linked carbamates and ureas of heterocyclic thioesters | GLIAMED, INC. | 2002-04-25 | — | — | US | claimed |
| EP-0959882-A4 | N-LINKED UREAS AND CARBAMATES OF HETEROCYCLIC THIOESTERS | HAMILTON GREGORY S (US) | 2001-12-05 | — | — | EP | claimed |
| EP-0959882-A1 | N-LINKED UREAS AND CARBAMATES OF HETEROCYCLIC THIOESTERS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-12-01 | — | — | EP | claimed |
| WO-1998029117-A1 | N-LINKED UREAS AND CARBAMATES OF HETEROCYCLIC THIOESTERS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-07-09 | — | — | WO | claimed |
| US-20020049199-A1 | N-linked carbamates and ureas of heterocyclic thioesters | GLIAMED, INC. | 2002-04-25 | — | — | US | disclosed |
| US-6274607-B1 | INHIBITORS OF PEPTIDYL-PROLYL ISOMERASE, OR ROTAMASE ENZYME ACTIVITY; DO NOT EXERT ANY IMMUNOSUPPRESSIVE ACTIVITY IN ADDITION TO THEIR NEUROTROPHIC ACTIVITY; BIOAVAILABILITY; POTENCY | GPI NIL HOLDINGS, INC. | 2001-08-14 | — | — | US | disclosed |
| US-5958949-A | INHIBITORS OF THE ENZYME ACTIVITY ASSOCIATED WITH IMMUNOPHILIN PROTEINS, PARTICULARLY PEPTIDYL-PROLYL ISOMERASE, OR ROTAMASE, ENZYME ACTIVITY; TREATMENT OF NERVOUS SYSTEM DISORDERS | GPI NIL HOLDINGS INC. (US) | 1999-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049199-A1 | N-linked carbamates and ureas of heterocyclic thioesters | FKBP8, FKBP1A, FKBP3 | KDM4E 1326/4885SMN1; SMN2 3103/4885POLB 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.